Comparison of Adverse Drug Reactions with Donepezil versus Memantine: Analysis of the French Pharmacovigilance Database

被引:10
|
作者
Babai, Samy [1 ]
Auriche, Pascal [2 ]
Le-Louet, Herve [1 ]
机构
[1] Hop Henri Mondor, Ctr Reg Pharmacovigilance, F-94010 Creteil, France
[2] Afssaps, St Denis, France
来源
THERAPIE | 2010年 / 65卷 / 03期
关键词
pharmacovigilance; adverse drug reactions; memantine; donepezil; Alzheimer disease; SEVERE ALZHEIMERS-DISEASE; CHOLINESTERASE-INHIBITORS; DEMENTIA; MODERATE; PREVALENCE; MANAGEMENT;
D O I
10.2515/therapie/2010008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background. Since donepezil and memantine are currently used for treating Alzheimer's disease, it is interesting to analyse, reassess and compare their safety profile in order to promote a better use. Methods. All spontaneous reports of suspected serious adverse drug reactions with donepezil alone and with memantine alone recorded in the French Pharmacovigilance Database during 6 years were retrospectively analysed. Results. The most frequent adverse drug reactions with donepezil alone and memantine alone were respectively: bradycardia (10% versus 7%), weakness (5% versus 6%) and convulsions (4% versus 3%). Conclusion. The most adverse drug events with donepezil and with memantine are associated with elderly people, even if they do not receive any other treatment. Donepezil and memantine have an acceptable safety profile but physicians should take special care when they prescribe any drug known to cause bradycardia or to reduce the epileptogenic threshold.
引用
收藏
页码:255 / 259
页数:5
相关论文
共 50 条
  • [1] Adverse Drug Reactions with Donepezil: Analysis of the French Pharmacovigilance Database
    Babai, S.
    Bourzam, W. E.
    Brocvielle, H.
    Le Loueet, H.
    DRUG SAFETY, 2008, 31 (10) : 912 - 912
  • [2] Adverse Drug Reactions with Donepezil: Analysis of the French Pharmacovigilance Database
    S. Babai
    W. E. Bourzam
    H. Brocvielle
    H. Le Louët
    Drug Safety, 2008, 31 : 885 - 885
  • [3] Adverse drug reactions to Posaconazole: analysis of the French Pharmacovigilance Database
    Eiden, C.
    Nicolosi, M.
    Peyriere, H.
    Blayac, J. P.
    Hillaire-Buys, D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 102 - 103
  • [4] Adverse drug reactions to pregabalin: an analysis of the French Pharmacovigilance Database
    Tavassoli, N.
    Montastruc, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 78 - 78
  • [5] Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database
    Kaguelidou, Florentia
    Beau-Salinas, Frederique
    Jonville-Bera, Annie Pierre
    Jacqz-Aigrain, Evelyne
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (04) : 1058 - 1068
  • [6] Adverse drug reactions of methylphenidate in French Pharmacovigilance Database
    Herlem, E.
    Marchaisseau, V.
    Germain, M. L.
    Trenque, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 55 - 55
  • [7] Hepatic Adverse Drug Reactions Associated with Methylprednisolone: Analysis of the French Pharmacovigilance Database
    Cottin, J.
    Pierre, S.
    Pizzoglio, V.
    Simon, C.
    Durieu, G.
    Gouraud, A.
    Kassai-koupai, B.
    Dumortier, J.
    DRUG SAFETY, 2018, 41 (11) : 1164 - 1164
  • [8] Adverse drug reactions of oxetorone: Study in the French Pharmacovigilance Database
    Ginisty, S.
    Vitu, L.
    Geniaux, H.
    Bergeron, S.
    Pinel, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 115 - 115
  • [9] Adverse drug reactions reported with antialdosterones to French Pharmacovigilance database
    Fedrizzi, S.
    Masson, R.
    Humbert, X.
    Gonzalez, C.
    Chenaf, C.
    Atzenhoffer, M.
    Sassier, M.
    Coquerel, A.
    Alexandre, J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 47 - 47
  • [10] Adverse drug reactions of carfilzomib: Study in the French Pharmacovigilance Database
    Farlan, K.
    Ginisty, S.
    Sassier, M.
    Damin-Pernik, M.
    Pinel, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 60 - 60